What is the 13F Pro Quality Score for STOK?

13F Pro ranks Stoke Therapeutics, Inc. (STOK) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View STOK's current score at https://13fpro.ai/research/STOK (free sign-up required for the full ranking).

Which hedge funds own the most STOK stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of STOK include RTW INVESTMENTS,, BlackRock,, FMR. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/STOK as soon as new 13F filings post.

Where does 13F Pro source STOK data?

All Stoke Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Stoke Therapeutics, Inc. files with the SEC under CIK 1623526. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is STOK in?

Stoke Therapeutics, Inc. (STOK) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is STOK research updated on 13F Pro?

STOK's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Stoke Therapeutics, Inc.(STOK)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1623526 STOK stock profile & AI dashboard →

13F Pro Quality Score

53.4/100

Rank #1,280 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

98.2/100

Profitability

56.0/100

Balance Sheet

37.4/100

Earnings Quality

30.0/100

Free Cash Flow

57.7/100

Institutional Flow

54.0/100

Revenue Scale

23.7/100

Dilution Risk

10.6/100

STOK Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Stoke Therapeutics, Inc. (STOK), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores STOK at 53.4/100 on a 32-signal composite quality model, placing it at rank #1,280 of 2,879 stocks — the top half of the AI-ranked universe. STOK scores in the top quartile across revenue growth (98.2). Areas of concern include revenue scale (23.7) and earnings quality (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 10.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Stoke Therapeutics, Inc. reports quarterly revenue of $6.2M, net income of $-50.0M, free cash flow of $-60.9M. Top institutional holders of STOK by reported 13-F value include RTW INVESTMENTS,, BlackRock,, FMR, based on the most recent SEC filings. STOK trades on the Nasdaq exchange and files with the SEC under CIK 1623526. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate STOK daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Stoke Therapeutics, Inc. directly from SEC EDGAR. Stoke Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 7 and 72 since 2023, currently 53.4 — an improving long-term trajectory across 48 quarterly and live scoring snapshots.

✦

Fun facts about Stoke Therapeutics, Inc.

Quirks, history, and lore behind STOK — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in Massachusetts · focused on rare genetic diseases.
2
The Numbers
A small-cap biotech with no approved products yet, meaning revenue is minimal and the company runs on cash from financings rather than product sales.
3
The History
Founded around 2014, the company was built around a novel scientific insight into how cells process genetic instructions — specifically, the idea that you can fix a broken gene by unlocking extra copies the body already hides.
4
The Secret
Its entire platform is built on a concept called RNA upregulation — instead of silencing bad genes (the crowded approach), it coaxes cells to produce more of the right protein from a naturally suppressed backup copy.
5
The Lore
Its lead program targets Dravet syndrome, a catastrophic childhood epilepsy, with a drug designed to boost output from the one good copy of the SCN1A gene patients still carry.
6
The Giveaway
The company's name is literally a verb — to stoke — because its whole mission is stoking gene expression upward, and its ticker on Nasdaq matches that action perfectly.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$6.2M

Net Income

Q1 2026

$-50.0M

Free Cash Flow

Q1 2026

$-60.9M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+316.3% YoY

$36.6MFY 2024

FY20 —FY22 $12.4MFY23 $8.8MFY24 $36.6M

Net Income

+15.0% YoY

$-89.0MFY 2024

FY20 $-52.2MFY22 $-101.1MFY23 $-104.7MFY24 $-89.0M

Operating Income

+11.7% YoY

$-101.4MFY 2024

FY20 $-53.0MFY22 $-104.4MFY23 $-114.8MFY24 $-101.4M

EPS (Diluted)

+30.7% YoY

$-1.65FY 2024

FY20 —FY22 $-2.60FY23 $-2.38FY24 $-1.65

Total Assets

+18.9% YoY

$271.6MFY 2024

FY20 $297.9MFY22 $256.1MFY23 $228.3MFY24 $271.6M

Op. Cash Flow

-7.1% YoY

$-86.9MFY 2024

FY20 $-42.2MFY22 $-31.9MFY23 $-81.1MFY24 $-86.9M

Metric	FY 2024	FY 2023	FY 2022	FY 2020	FY 2019	FY 2018
Revenue	$36.6M +316.3%	$8.8M -29.2%	$12.4M	—	—	—
Net Income	$-89.0M +15.0%	$-104.7M -3.6%	$-101.1M -93.5%	$-52.2M -61.6%	$-32.3M -158.2%	$-12.5M
Operating Income	$-101.4M +11.7%	$-114.8M -10.0%	$-104.4M -96.7%	$-53.0M -48.7%	$-35.7M -179.1%	$-12.8M
EPS (Diluted)	$-1.65 +30.7%	$-2.38 +8.5%	$-2.60	—	—	—
Total Assets	$271.6M +18.9%	$228.3M -10.8%	$256.1M -14.0%	$297.9M +30.2%	$228.8M +112.7%	$107.5M
Operating Cash Flow	$-86.9M -7.1%	$-81.1M -154.4%	$-31.9M +24.5%	$-42.2M -36.0%	$-31.1M -183.2%	$-11.0M

AI Insight: STOK Financial Trends

Stoke's Q1 2025 spike ($159M revenue, $113M net income) appears to be a non-recurring event; business has reverted to heavy losses with collapsing cash generation.

• Q1 2025 showed anomalous profitability ($159M revenue, $113M net income, $132M operating cash flow), but Q2–Q1 2026 revenues collapsed to $1–14M with sustained operating losses.

• Operating cash flow deteriorated sharply: $132M in Q1 2025 to -$61M in Q1 2026, signaling severe cash burn acceleration in core operations.

• Equity oscillated between $229M–$395M over eight quarters; balance sheet appears supported but underlying cash generation is negative and worsening.

⚠ Q1 2026 operating cash flow of -$61M is the worst on record; runway and sustainability of current equity base require urgent scrutiny.

⚠ Q1 2025 likely reflects a one-time licensing/milestone event; investigate nature and whether repeatable revenue drivers exist.

AI Insight: STOK Ratio Trends

Stoke remains unprofitable across all return metrics; Q1 2025's anomalous profitability was not sustained.

• ROE deteriorated from -50.6% in Q1 2026 to -65.8% in Q4 2025, reflecting deepening equity losses.

• ROIC declined from -23.8% in Q4 2024 to -69.7% in Q4 2025, signaling worsening capital efficiency.

• Q1 2025 showed anomalous 70.2% OpMargin and 71.2% NPM; Q2 2025 swung to -197.6% OpMargin, suggesting accounting volatility.

⚠ TTM ROIC at -46.9% vs. Q1 2026 quarterly -54.1% indicates deteriorating recent-quarter performance despite TTM averaging.

⚠ Persistent negative ROA (-45.1% Q1 2026) and ROE (-50.6%) signal no path to profitability visible in trailing data.

Get alerted when STOK's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Stoke Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of STOK

RTW INVESTMENTS, LP
$183.1M5,623,525 sh
BlackRock, Inc.
$175.4M5,385,714 sh
FMR LLC
$175.3M5,383,666 sh
Lynx1 Capital Management LP
$155.1M4,763,673 sh
Redmile Group, LLC
$135.6M4,164,120 sh
MORGAN STANLEY
$111.5M3,423,280 sh
BAKER BROS. ADVISORS LP
$108.6M3,336,697 sh
TORONTO DOMINION BANK
$103.3M3,173,258 sh
WELLINGTON MANAGEMENT GROUP LLP
$100.8M3,095,700 sh
BVF INC/IL
$82.9M2,547,557 sh

Fund	Value	Shares
RTW INVESTMENTS, LP	$183.1M	5,623,525
BlackRock, Inc.	$175.4M	5,385,714
FMR LLC	$175.3M	5,383,666
Lynx1 Capital Management LP	$155.1M	4,763,673
Redmile Group, LLC	$135.6M	4,164,120
MORGAN STANLEY	$111.5M	3,423,280
BAKER BROS. ADVISORS LP	$108.6M	3,336,697
TORONTO DOMINION BANK	$103.3M	3,173,258
WELLINGTON MANAGEMENT GROUP LLP	$100.8M	3,095,700
BVF INC/IL	$82.9M	2,547,557

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put STOK on your watchlist

Track score changes the day Stoke Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is STOK a good stock to buy?

13F Pro's AI-powered analysis of Stoke Therapeutics, Inc. (STOK) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for STOK are available on the STOK stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own STOK?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling STOK. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Stoke Therapeutics, Inc.'s investment landscape.